Could a simple drug stop deadly organ failure after surgery?
NCT ID NCT07404358
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if a drug called dalargin can prevent serious organ problems like kidney injury, lung failure, or heart damage after major abdominal surgery. About 200 adults having high-risk surgery will get either dalargin or a placebo for 3 days. The goal is to see if dalargin reduces these life-threatening complications and helps people recover better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABDOMINAL SURGERY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center
Moscow, 125284, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test score may flag High-Risk esophageal surgery patients
- A simple sensor on the back could warn of kidney danger during heart surgery
- CT scans may predict breast reconstruction flap failure
- Could belly pressure predict heart surgery outcomes?
- Could a simple ultrasound and nutrition score forecast hip fracture recovery?
- Could a surgeon's mental health impact your surgery outcome?